Details for New Drug Application (NDA): 210014
✉ Email this page to a colleague
NDA 210014 describes DESVENLAFAXINE SUCCINATE, which is a drug marketed by Actavis Labs Fl, Alembic, Hikma, Lupin Ltd, Macleods Pharms Ltd, Medicap Labs, Pharmobedient, Rubicon Research, Yichang Humanwell, and Zydus Pharms, and is included in ten NDAs. It is available from nineteen suppliers. Additional details are available on the DESVENLAFAXINE SUCCINATE profile page.
The generic ingredient in DESVENLAFAXINE SUCCINATE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.
The generic ingredient in DESVENLAFAXINE SUCCINATE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.
Summary for 210014
| Tradename: | DESVENLAFAXINE SUCCINATE |
| Applicant: | Yichang Humanwell |
| Ingredient: | desvenlafaxine succinate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 210014
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 210014 | ANDA | A-S Medication Solutions | 50090-6738 | 50090-6738-0 | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50090-6738-0) |
| DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 210014 | ANDA | Slate Run Pharmaceuticals, LLC | 70436-012 | 70436-012-04 | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (70436-012-04) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 50MG BASE | ||||
| Approval Date: | Oct 1, 2018 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 100MG BASE | ||||
| Approval Date: | Oct 1, 2018 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 25MG BASE | ||||
| Approval Date: | Oct 13, 2020 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
